A Form 4 filed on November 20, 2026 reports that Dragan Cicic, SVP and Chief Development Officer of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), disposed of 6,933 shares of common stock on November 18, 2026 to satisfy tax withholding obligations connected to the performance-based vesting of restricted stock units.
Key Highlights
- Reporting person: Dragan Cicic, SVP and Chief Development Officer of SELLAS Life Sciences Group, Inc.
- Transaction: 6,933 shares of common stock disposed of (transaction code S) on November 18, 2026 at a price of $19.178 per share.
- Purpose: Shares were sold to satisfy tax withholding obligations arising from the performance-based vesting of previously granted restricted stock units.
- Triggering event: The RSU vesting followed SELLAS meeting the primary endpoint in its Phase 3 REGAL study, according to the filing.
- Remaining ownership: Following the transaction, Cicic directly beneficially owned 557,361 shares of common stock.
- Nature of sale: The filing states the sales "are mandated as part of the Issuer's election under its equity incentive plans" and "do not represent discretionary trades by the Reporting Person."
SELLAS CDO Cicic's Tax-Withholding Sale Follows Phase 3 REGAL Study Milestone
According to the Form 4 filed with the SEC on November 20, 2026, Dragan Cicic, serving as SVP and Chief Development Officer at SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), sold 6,933 shares of common stock on November 18, 2026 at a price of $19.178 per share. The filing classifies this transaction under code "S" and identifies the shares as disposed of (D) in Table I covering non-derivative securities.
The filing's footnote explains that the sale represents shares withheld to cover the reporting person's tax obligation resulting from the performance-based vesting of certain previously granted restricted stock units. That vesting was triggered by SELLAS meeting the primary endpoint in its Phase 3 REGAL study. The footnote further states that these sales are mandated under the issuer's equity incentive plan through a "sell to cover" mechanism and "do not represent discretionary trades by the Reporting Person." No derivative securities transactions were reported in Table II.
Following the reported transaction, Cicic directly beneficially owned 557,361 shares of SELLAS Life Sciences common stock, according to the filing. The Form 4 was signed by Kostantinos Skordalos acting under a power of attorney on behalf of Dragan Cicic and was filed on November 20, 2026.
What Was Disclosed
The filing disclosed a mandatory tax-withholding sale of 6,933 common shares by SELLAS SVP Dragan Cicic at $19.178 per share on November 18, 2026, connected to RSU vesting triggered by the Phase 3 REGAL study's primary endpoint, leaving him with 557,361 shares directly held.



Please wait processing your request...